GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

apecotrep   Click here for help

GtoPdb Ligand ID: 14343

Synonyms: BI 764198 | BI-764198 | compound 17 [US10800757B2]
Compound class: Synthetic organic
Comment: Apecotrep (BI 764198) is an orally bioavailable transient receptor potential channel C6 (TRPC6) inhibitor [1,6]. Hyperactivity of TRPC6 is linked to podocyte dysfunction in the nephrotic channelopathy, focal and segmental glomerulosclerosis (FSGS) [2-4], hence TRPC6 inhibition is proposed as a novel FSGS therapeutic modality [5].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 101.87
Molecular weight 423.44
XLogP 1.17
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES COC1=CC(=NC=C1OC2=CC=C(C=C2)F)C(=O)N3CCC(CC3)C4=CC=C(N)N=N4
Isomeric SMILES COC1=CC(=NC=C1OC2=CC=C(C=C2)F)C(=O)N3CCC(CC3)C4=NN=C(C=C4)N
InChI InChI=1S/C22H22FN5O3/c1-30-19-12-18(25-13-20(19)31-16-4-2-15(23)3-5-16)22(29)28-10-8-14(9-11-28)17-6-7-21(24)27-26-17/h2-7,12-14H,8-11H2,1H3,(H2,24,27)
InChI Key JUALOUHZJJERQT-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
References
1. Bouyssou T, Gottschling D, Heine N, Keenan LLS, Lowe MD, Ravazi H, Sarko CR, Surprenant S, Takahashi H, Turner MR et al.. (2020)
Inhibitors of TRPC6.
Patent number: US10800757B2. Assignee: Boehringer Ingelheim International GmbH, Hydra Biosciences LLC. Priority date: 25/10/2018. Publication date: 13/10/2020.
2. Jiang L, Ding J, Tsai H, Li L, Feng Q, Miao J, Fan Q. (2011)
Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation.
Exp Biol Med (Maywood), 236 (2): 184-93. [PMID:21321315]
3. Mukerji N, Damodaran TV, Winn MP. (2007)
TRPC6 and FSGS: the latest TRP channelopathy.
Biochim Biophys Acta, 1772 (8): 859-68. [PMID:17459670]
4. Shabaka A, Tato Ribera A, Fernández-Juárez G. (2020)
Focal Segmental Glomerulosclerosis: State-of-the-Art and Clinical Perspective.
Nephron, 144 (9): 413-427. [PMID:32721952]
5. Trachtman H. (2020)
Emerging drugs for treatment of focal segmental glomerulosclerosis.
Expert Opin Emerg Drugs, 25 (3): 367-375. [PMID:32729368]
6. Trachtman H, Kretzler M, Desmond HE, Choi W, Manuel RC, Soleymanlou N. (2023)
TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design.
Kidney Int Rep, 8 (12): 2822-2825. [PMID:38106603]
7. Trachtman H, Kretzler M, Gesualdo L, Cross N, Workeneh B, Kaulfield J, Meijers B, Ye Z, Chen Q, Derebail VK et al.. (2026)
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198.
The Lancet, Epub ahead of print. DOI: 10.1016/S0140-6736(25)02255-X
8. Ware LB, Soleymanlou N, McAuley DF, Estrada V, Diaz GA, Lacamera P, Kaste R, Choi W, Gupta A, Welte T. (2023)
TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.
Thorax, 78 (8): 816-824. [PMID:37024277]
9. Yonemura T, Sarashina A, Tachibana Y, Retlich S, Soleymanlou N. (2025)
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men.
Expert Opin Investig Drugs, 34 (5): 425-433. [PMID:40402558]